Treatment
Belatacept clinical trials
We’re tracking 11 recruiting studies that include Belatacept, each written for real people, not researchers, below.
Recruiting studies
- NCT06478017RecruitingPhase 2
Belatacept for heart transplant patients
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
Los Angeles, CaliforniaAges 18–71 - NCT04477629RecruitingPhase 2
Belatacept for first-time heart transplant recipients
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
New York, New YorkAges 18–75 - NCT04877288RecruitingPhase 3
Switch some teen kidney transplant patients to belatacept
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
Birmingham, AlabamaAges 12–17 - NCT04180085RecruitingPhase 2
Belatacept to protect kidneys in heart transplant patients
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
BordeauxAges 18 years+ - NCT05562869RecruitingPhase 3
Belatacept instead of tacrolimus for early kidney graft problems
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Nantes, Loire AtlantiqueAges 18–99 - NCT06291077RecruitingPhase 4
Belatacept vs anticalcineurins after kidney transplant
This study is comparing two medications after kidney transplant: Belatacept and anticalcineurins (like tacrolimus). It looks at how each affects blood vessel health. If you are more than a year post-transplant and have stable kidney function, you may be eligible.
RouenAges 18–75 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT02310867RecruitingPhase 2
Immunotherapy to help grafts heal for people with limb loss
This Phase 2 study tests an immune-targeting treatment to help a transplanted tissue “graft” integrate and heal better after limb loss. It may help by reducing problems with healing and rejection, but you must be able to complete frequent follow-up visits and testing.
Durham, North CarolinaAges 18–65 - NCT06336863Enrolling by invitation
DNA test to help kidney transplant patients switch to a single anti-rejection drug
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
Dallas, TexasAges 18 years+ - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Birmingham, AlabamaAges 13–20 - NCT07096453RecruitingPhase 1/Phase 2
CMV prevention in kidney transplant patients switching to belatacept
This trial tests whether an experimental drug (CMVIG) can prevent CMV infection in kidney transplant patients who are switching to or already on belatacept, a newer immunosuppressant. It may help protect those at higher risk for CMV.
Minneapolis, MinnesotaAges 18–70
What Belatacept is being studied for
Conditions with recruiting Belatacept studies.
Common questions
- Are there clinical trials studying Belatacept?
- Yes. Clin2 currently lists 11 recruiting studies that include Belatacept, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Belatacept trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Belatacept an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Belatacept or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.